In this prospective study of unselected and consecutively diagnosed CRC patients, we assessed the performance of currently used clinical guidelines (AM II and RBG) against three separate molecular tumour tests (MSI, BRAF and MLH1 methylation analyses) in the identification of possible LS. Here, MLH1 is linked to neoplasm.